Turn Abandoned Patents Into Profit
The pharmaceutical industry operates on a high-risk model where the cost of a single drug approval ranges from $1 billion […]
Turn Abandoned Patents Into Profit Read Post »
Insights
Drug Reformulation Strategy: Buy Seven Years of Exclusivity for $20 Million
Pharmaceutical manufacturers face a revenue contraction of 62% from their top-selling assets by 2030.1 Blockbuster drugs representing $236 billion in
Drug Reformulation Strategy: Buy Seven Years of Exclusivity for $20 Million Read Post »
Sell Before the Cliff Drops: A BD Playbook for Biopharma Equipment Suppliers
How to use market automation and drug patent intelligence to build pipeline before generic entry kills your best customers’ budgets
Sell Before the Cliff Drops: A BD Playbook for Biopharma Equipment Suppliers Read Post »
Forecasting Generic Entry: Combining FDA Orange Book with Paragraph IV Notice Letters
Pharmaceutical companies lose between $200 billion and $400 billion in annual revenue to patent expirations between 2025 and 2030. This
Forecasting Generic Entry: Combining FDA Orange Book with Paragraph IV Notice Letters Read Post »
Win the Patent Fight: Hatch-Waxman Litigation Strategies for Brand and Generic Manufacturers
The Statute That Rewired the Drug Industry In September 1984, President Reagan signed two pieces of legislation that had been
Why Branded Generics Dominate the Pharmaceutical Landscape in Emerging Markets
Branded Generics: The $400 Billion Business That Big Pharma Can’t Ignore In the summer of 2022, a pharmacist in Lagos
Why Branded Generics Dominate the Pharmaceutical Landscape in Emerging Markets Read Post »
Bundle or Lose: The Biopharma Data Provider’s Guide to Selling Patent, Clinical, and Litigation Intelligence Together
The companies winning enterprise contracts in biopharma data intelligence aren’t selling better patent databases. They’re selling a connected answer to
The patent cliff is not a crisis for equipment suppliers. It’s a sales calendar: Sell Continuous Manufacturing Before the Drug Patent Cliff Hits
Every major drug patent expiration triggers a predictable downstream event: the originator company races to defend margin, and a dozen
Oncology’s Patent Cliff Is Your Sales Pipeline: A Business Development Guide for High-Containment Equipment Suppliers Targeting Oncology Loss-of-Exclusivity Opportunities
The LOE Wave Nobody in Equipment Sales Is Talking About Between 2024 and 2029, roughly $130 billion worth of branded
